Copenhagen and Oslo, 12th October 2012, 2012-10-12 16:06 CEST (GLOBE NEWSWIRE) --
Affitech A/S, (NASDAQ OMX: AFFI), the antibody medicines company, announced today that Trans Nova Investments Limited, the largest shareholder in Affitech A/S with 76,78% ownership has agreed to extend the due date for the Euro 1.5 million short term loan provided in July 2012 and paid to Affitech in three tranches in July, August and September 2012 . The due date has been extended from 16th October, 2012 until 16th January, 2013. The other conditions for the loan remain unchanged.
Affitech A/S is a publicly traded (NASDAQ OMX Copenhagen) biotech company headquartered in Copenhagen, Denmark with R&D facilities in Oslo, Norway. The company utilizes a range of proprietary antibody technologies for the discovery of fully human antibodies for application in oncology, inflammation and other disease areas. Affitech A/S antibody drugs targeting molecules on the cell surface are developed through the Company’s proprietary CBAS™ (Cell Based Antibody Selection). Affitech develops its two leading antibody drug candidates AT001/r84 and AT008/CCR4 in collaboration with its Russian partner IBC Generium. Further information is available at www.affitech.com.
Stig Jarle Pettersen, CFO
Tel +47 9096 0336
Randi Krogsgaard, Director IR & Communications
Tel # +45 2320 1001, e-mail: firstname.lastname@example.org
Affitech A/S Logo